retatrutide fda approval timeline 2025 approval: status, clinical trial results, and when it could be available June 8, 2026: Reckless physicians

Diabetes Care 36 , 34603468 (2013)

Consumers struggling to access the branded GLP-1 medications theyve been prescribed can visit www.hims.com/weight-loss/supply-tracker or www.forhers.com/weight-loss/supply-tracker to share more about their experience

The company received a $150,000 fine for, among other things, making claims about GLP-1 effectiveness without proper evidence, and manipulating consumer reviews

Common side effects, when they occur, are typically mild and gastrointestinal in nature, including bloating, flatulence, and temporary changes in bowel habits

Davies M, Faerch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al

This seamless process eliminates waiting rooms, travel, and unnecessary delays